Tags

Type your tag names separated by a space and hit enter

Long-term bioavailability after a single oral or intramuscular administration of 600,000 IU of ergocalciferol or cholecalciferol: implications for treatment and prophylaxis.
J Clin Endocrinol Metab. 2013 Jul; 98(7):2709-15.JC

Abstract

CONTEXT

We previously showed that a single high dose of oral (po) cholecalciferol (D₃) sharply increases serum 25-hydroxyvitamin D [25(OH)D].

OBJECTIVE

We evaluated the long-term bioavailability and metabolism of a single po or intramuscular (im) high dose of ergocalciferol (D₂) or D₃.

DESIGN

This was a prospective intervention study.

SETTING

The study was conducted in an ambulatory care setting.

PATIENTS

Participants were 24 subjects with hypovitaminosis D.

INTERVENTIONS

A single dose of 600,000 IU of po or im D₂ or D₃ was administered.

MAIN OUTCOME MEASURES

Serum 25(OH)D and 1,25-dihydroxyvitamin D [1,25(OH)₂D] were measured at baseline and at days 30, 60, 90, and 120 by RIA. Serum 1,25(OH)₂D₂, 1,25-dihydroxyvitamin D₃ [1,25(OH)₂D₃], 24,25-hydroxyvitamin D₂ [24,25(OH)D₂], and 24,25-hydroxyvitamin D₃ [24,25(OH)D₃] were measured by liquid chromatography-tandem mass spectrometry in a subgroup of patients receiving the po formulations.

RESULTS

The areas under the curve of 25(OH)D after D₃ were significantly higher than those after D₂ (P < .0001). Serum 25(OH)D basal difference significantly increased at day 30 with po D₂ and D₃ (P < .01 and P < .0001) and up to day 90 with po D₃ (P < .01). The im formulations produced a slow increased, and values peaked at day 120 relative to the other time points (P < .0001). We found a decrease in 1,25(OH)₂D at day 30 (P < .05) and up to day 120 (P < .001) and an increase in 1,25(OH)₂D₂ at day 30 (P < .01) and up to day 120 (P < .01) after po D₂. Oral D₂ and D₃ produced increases in 24,25(OH)D₂ and 24,25(OH)D₃, respectively, at day 30 (P < .001).

CONCLUSIONS

A po dose of 600,000 IU of D₂ or D₃ is initially more effective in increasing serum 25(OH)D than the equivalent im dose and is rapidly metabolized. Our RIA assay for 1,25(OH)₂D may not recognize 1,25(OH)₂D₂.

Authors+Show Affiliations

Department of Internal Medicine and Medical Disciplines, Sapienza Rome University, 00161 Rome, Italy. cristianac@alice.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

23766519

Citation

Cipriani, Cristiana, et al. "Long-term Bioavailability After a Single Oral or Intramuscular Administration of 600,000 IU of Ergocalciferol or Cholecalciferol: Implications for Treatment and Prophylaxis." The Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 7, 2013, pp. 2709-15.
Cipriani C, Romagnoli E, Pepe J, et al. Long-term bioavailability after a single oral or intramuscular administration of 600,000 IU of ergocalciferol or cholecalciferol: implications for treatment and prophylaxis. J Clin Endocrinol Metab. 2013;98(7):2709-15.
Cipriani, C., Romagnoli, E., Pepe, J., Russo, S., Carlucci, L., Piemonte, S., Nieddu, L., McMahon, D. J., Singh, R., & Minisola, S. (2013). Long-term bioavailability after a single oral or intramuscular administration of 600,000 IU of ergocalciferol or cholecalciferol: implications for treatment and prophylaxis. The Journal of Clinical Endocrinology and Metabolism, 98(7), 2709-15. https://doi.org/10.1210/jc.2013-1586
Cipriani C, et al. Long-term Bioavailability After a Single Oral or Intramuscular Administration of 600,000 IU of Ergocalciferol or Cholecalciferol: Implications for Treatment and Prophylaxis. J Clin Endocrinol Metab. 2013;98(7):2709-15. PubMed PMID: 23766519.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term bioavailability after a single oral or intramuscular administration of 600,000 IU of ergocalciferol or cholecalciferol: implications for treatment and prophylaxis. AU - Cipriani,Cristiana, AU - Romagnoli,Elisabetta, AU - Pepe,Jessica, AU - Russo,Stefania, AU - Carlucci,Luciano, AU - Piemonte,Sara, AU - Nieddu,Luciano, AU - McMahon,Donald J, AU - Singh,Ravinder, AU - Minisola,Salvatore, Y1 - 2013/06/13/ PY - 2013/6/15/entrez PY - 2013/6/15/pubmed PY - 2013/10/1/medline SP - 2709 EP - 15 JF - The Journal of clinical endocrinology and metabolism JO - J Clin Endocrinol Metab VL - 98 IS - 7 N2 - CONTEXT: We previously showed that a single high dose of oral (po) cholecalciferol (D₃) sharply increases serum 25-hydroxyvitamin D [25(OH)D]. OBJECTIVE: We evaluated the long-term bioavailability and metabolism of a single po or intramuscular (im) high dose of ergocalciferol (D₂) or D₃. DESIGN: This was a prospective intervention study. SETTING: The study was conducted in an ambulatory care setting. PATIENTS: Participants were 24 subjects with hypovitaminosis D. INTERVENTIONS: A single dose of 600,000 IU of po or im D₂ or D₃ was administered. MAIN OUTCOME MEASURES: Serum 25(OH)D and 1,25-dihydroxyvitamin D [1,25(OH)₂D] were measured at baseline and at days 30, 60, 90, and 120 by RIA. Serum 1,25(OH)₂D₂, 1,25-dihydroxyvitamin D₃ [1,25(OH)₂D₃], 24,25-hydroxyvitamin D₂ [24,25(OH)D₂], and 24,25-hydroxyvitamin D₃ [24,25(OH)D₃] were measured by liquid chromatography-tandem mass spectrometry in a subgroup of patients receiving the po formulations. RESULTS: The areas under the curve of 25(OH)D after D₃ were significantly higher than those after D₂ (P < .0001). Serum 25(OH)D basal difference significantly increased at day 30 with po D₂ and D₃ (P < .01 and P < .0001) and up to day 90 with po D₃ (P < .01). The im formulations produced a slow increased, and values peaked at day 120 relative to the other time points (P < .0001). We found a decrease in 1,25(OH)₂D at day 30 (P < .05) and up to day 120 (P < .001) and an increase in 1,25(OH)₂D₂ at day 30 (P < .01) and up to day 120 (P < .01) after po D₂. Oral D₂ and D₃ produced increases in 24,25(OH)D₂ and 24,25(OH)D₃, respectively, at day 30 (P < .001). CONCLUSIONS: A po dose of 600,000 IU of D₂ or D₃ is initially more effective in increasing serum 25(OH)D than the equivalent im dose and is rapidly metabolized. Our RIA assay for 1,25(OH)₂D may not recognize 1,25(OH)₂D₂. SN - 1945-7197 UR - https://www.unboundmedicine.com/medline/citation/23766519/Long_term_bioavailability_after_a_single_oral_or_intramuscular_administration_of_600000_IU_of_ergocalciferol_or_cholecalciferol:_implications_for_treatment_and_prophylaxis_ L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2013-1586 DB - PRIME DP - Unbound Medicine ER -